The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Immunotherapeutic uses of CpG oligodeoxynucleotides
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508
Self-citationToll-like receptors in the induction of the innate immune response
Aderem, A., & Ulevitch, R. J. (2000) · Nature · doi:10.1038/35021228 · Cited by 3,064
Wegmann, T. G., Lin, H., Guilbert, L., & Mosmann, T. R. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90235-d · Cited by 2,852
Predominant TH2-like Bronchoalveolar T-Lymphocyte Population in Atopic Asthma
Robinson, D. S., Hamid, Q., Ying, S., Tsicopoulos, A., Barkans, J., Bentley, A. M., Corrigan, C., Durham, S. R., & Kay, A. B. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201303260504 · Cited by 2,768
Innate Immunity: The Virtues of a Nonclonal System of Recognition
Medzhitov, R., & Janeway, C. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80412-2 · Cited by 2,434
Kadowaki, N., Ho, S., Antonenko, S., de Waal Malefyt, R., Kastelein, R. A., Bazan, F., & Liu, Y.-J. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.863 · Cited by 1,964 · cited 1×
“In mice, immune cells of the myeloid lineage (including monocytes, macrophages and myeloid DCs) express TLR9 and respond to CpG stimulation, whereas in humans, these cell types generally do not express TLR9 and cannot be directly activated by CpG ODN”
BackgroundHornung, V., Rothenfusser, S., Britsch, S., Krug, A., Jahrsdörfer, B., Giese, T., Endres, S., & Hartmann, G. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4531 · Cited by 1,935
Innate immunity: impact on the adaptive immune response
Medzhitov, R., & Janeway, C. A. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80152-5 · Cited by 1,558
Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition
Bauer, S., Kirschning, C. J., Häcker, H., Redecke, V., Hausmann, S., Akira, S., Wagner, H., & Lipford, G. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161293498 · Cited by 1,533
Cited by
IRF-7 is the master regulator of type-I interferon-dependent immune responses
Honda, K., Yanai, H., Negishi, H., Asagiri, M., Sato, M., Mizutani, T., Shimada, N., Ohba, Y., Takaoka, A., Yoshida, N., et al. (2005) · Nature · doi:10.1038/nature03464 · Cited by 2,245
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Honda, K., & Taniguchi, T. (2006) · Nature Reviews Immunology · doi:10.1038/nri1900 · Cited by 1,676
Type I Inteferon Gene Induction by the Interferon Regulatory Factor Family of Transcription Factors
Honda, K., Takaoka, A., & Taniguchi, T. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.009 · Cited by 1,393
Therapeutic potential of Toll-like receptor 9 activation
Krieg, A. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2059 · Cited by 1,246
DNA Nanotechnology-Enabled Drug Delivery Systems
Hu, Q., Li, H., Wang, L., Gu, H., & Fan, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00663 · Cited by 1,118
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,078
Spatiotemporal regulation of MyD88–IRF-7 signalling for robust type-I interferon induction
Honda, K., Ohba, Y., Yanai, H., Negishi, H., Mizutani, T., Takaoka, A., Taya, C., & Taniguchi, T. (2005) · Nature · doi:10.1038/nature03547 · Cited by 912
Toll-like receptor function and signaling
Kaisho, T., & Akira, S. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.02.023 · Cited by 898
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869
Castellino, F., Huang, A. Y., Altan-Bonnet, G., Stoll, S., Scheinecker, C., & Germain, R. N. (2006) · Nature · doi:10.1038/nature04651 · Cited by 855
Origins, structures, and functions of circulating DNA in oncology
Thierry, A. R., El Messaoudi, S., Gahan, P. B., Anker, P., & Stroun, M. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9629-x · Cited by 818
Li, J., Pei, H., Zhu, B., Liang, L., Wei, M., He, Y., Chen, N., Li, D., Huang, Q., & Fan, C. (2011) · ACS Nano · doi:10.1021/nn202774x · Cited by 748
Toll-Like Receptor 8-Mediated Reversal of CD4 + Regulatory T Cell Function
Peng, G., Guo, Z., Kiniwa, Y., Voo, K. S., Peng, W., Fu, T., Wang, D. Y., Li, Y., Wang, H. Y., & Wang, R.-F. (2005) · Science · doi:10.1126/science.1113401 · Cited by 746
Toll-Like Receptors in Antiviral Innate Immunity
Lester, S. N., & Li, K. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.11.024 · Cited by 735
Chieppa, M., Rescigno, M., Huang, A. Y. C., & Germain, R. N. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061884 · Cited by 713
Strategies and Molecular Design Criteria for 3D Printable Hydrogels
Jungst, T., Smolan, W., Schacht, K., Scheibel, T., & Groll, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00303 · Cited by 712
HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses
Yanai, H., Ban, T., Wang, Z., Choi, M. K., Kawamura, T., Negishi, H., Nakasato, M., Lu, Y., Hangai, S., Koshiba, R., et al. (2009) · Nature · doi:10.1038/nature08512 · Cited by 688
Speiser, D. E., Líénard, D., Rufer, N., Rubio‐Godoy, V., Rimoldi, D., Lejeune, F. J., Krieg, A. Μ., Cerottini, J., & Romero, P. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523373 · Cited by 640
Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin
Coban, C., Ishii, K. J., Kawai, T., Hemmi, H., Sato, S., Uematsu, S., Yamamoto, M., Takeuchi, O., Itagaki, S., Kumar, N., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041836 · Cited by 640
Vaccines: past, present and future
Plotkin, S. A. (2005) · Nature Medicine · doi:10.1038/nm1209 · Cited by 592
Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing
Deleavey, G. F., & Damha, M. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.011 · Cited by 589
Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists
Vollmer, J., & Krieg, A. M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.12.008 · Cited by 585
Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G., & Colombo, M. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4262 · Cited by 549
Kim, J., Li, W. A., Choi, Y., Lewin, S. A., Verbeke, C. S., Dranoff, G., & Mooney, D. J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3071 · Cited by 541
Toll-like Receptors and Type I Interferons
Uematsu, S., & Akira, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.r700009200 · Cited by 498
Aguilar, J. C., & Rodríguez, E. G. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.111 · Cited by 494
Molecular and cellular signatures of human vaccine adjuvants
Mosca, F., Tritto, E., Muzzi, A., Monaci, E., Bagnoli, F., Iavarone, C., O'Hagan, D., Rappuoli, R., & De Gregorio, E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804699105 · Cited by 492
Multifunctional biomolecule nanostructures for cancer therapy
Wang, J., Li, Y., & Nie, G. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00315-x · Cited by 488
Toll-like receptor 9–induced type I IFN protects mice from experimental colitis
Katakura, K., Lee, J., Rachmilewitz, D., Li, G., Eckmann, L., & Raz, E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci22996 · Cited by 451
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2021) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 450
Infection-mimicking materials to program dendritic cells in situ
Ali, O. A., Huebsch, N., Cao, L., Dranoff, G., & Mooney, D. J. (2009) · Nature Materials · doi:10.1038/nmat2357 · Cited by 434
Romagnani, S. (2004) · Immunology · doi:10.1111/j.1365-2567.2004.01925.x · Cited by 431
Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity
Shi, S., Zhu, H., Xia, X., Liang, Z., Ma, X., & Sun, B. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.055 · Cited by 423
Regulation of the T cell response
Romagnani, S. (2006) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2006.02606.x · Cited by 401
Carbon nanotubes: a novel material for multifaceted applications in human healthcare
Kumar, S., Rani, R., Dilbaghi, N., Tankeshwar, K., & Kim, K.-H. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00517a · Cited by 397
TLR9 as a key receptor for the recognition of DNA☆
KUMAGAI, Y., TAKEUCHI, O., & AKIRA, S. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.12.004 · Cited by 387
Hu, S., Xie, Z., Onishi, A., Yu, X., Jiang, L., Lin, J., Rho, H.-S., Woodard, C., Wang, H., Jeong, J.-S., et al. (2009) · Cell · doi:10.1016/j.cell.2009.08.037 · Cited by 383
Efficient Nanovaccine Delivery in Cancer Immunotherapy
Zhu, G., Zhang, F., Ni, Q., Niu, G., & Chen, X. (2017) · ACS Nano · doi:10.1021/acsnano.7b00978 · Cited by 374
Wilson, N. S., Behrens, G. M. N., Lundie, R. J., Smith, C. M., Waithman, J., Young, L., Forehan, S. P., Mount, A., Steptoe, R. J., Shortman, K. D., et al. (2006) · Nature Immunology · doi:10.1038/ni1300 · Cited by 373
Hou, B., Reizis, B., & DeFranco, A. L. (2008) · Immunity · doi:10.1016/j.immuni.2008.05.016 · Cited by 363
Henault, J., Martinez, J., Riggs, J. M., Tian, J., Mehta, P., Clarke, L., Sasai, M., Latz, E., Brinkmann, M. M., Iwasaki, A., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.09.014 · Cited by 348
Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy
Zhu, G., Lynn, G. M., Jacobson, O., Chen, K., Liu, Y., Zhang, H., Ma, Y., Zhang, F., Tian, R., Ni, Q., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02191-y · Cited by 315
Self-citationThomas, S. N., Vokali, E., Lund, A. W., Hubbell, J. A., & Swartz, M. A. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.003 · Cited by 310
DNA hydrogel-based gene editing and drug delivery systems
Mo, F., Jiang, K., Zhao, D., Wang, Y., Song, J., & Tan, W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.018 · Cited by 304
Molecular Repolarisation of Tumour-Associated Macrophages
Van Dalen, F. J., Van Stevendaal, M. H. M. E., Fennemann, F. L., Verdoes, M., & Ilina, O. (2018) · Molecules · doi:10.3390/molecules24010009 · Cited by 302
Mellor, A. L., Baban, B., Chandler, P. R., Manlapat, A., Kahler, D. J., & Munn, D. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5601 · Cited by 290
A DNA Nanostructure Platform for Directed Assembly of Synthetic Vaccines
Liu, X., Xu, Y., Yu, T., Clifford, C., Liu, Y., Yan, H., & Chang, Y. (2012) · Nano Letters · doi:10.1021/nl301877k · Cited by 289
Agger, E. M., Rosenkrands, I., Hansen, J., Brahimi, K., Vandahl, B. S., Aagaard, C., Werninghaus, K., Kirschning, C., Lang, R., Christensen, D., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003116 · Cited by 287
Overcoming the Innate Immune Response to Small Interfering RNA
Judge, A., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.179 · Cited by 284
Judge, A., McClintock, K., Phelps, J. R., & MacLachlan, I. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.014 · Cited by 280
Engineering Multifunctional DNA Hybrid Nanospheres through Coordination‐Driven Self‐Assembly
Li, M., Wang, C., Di, Z., Li, H., Zhang, J., Xue, W., Zhao, M., Zhang, K., Zhao, Y., & Li, L. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201810735 · Cited by 277
Paget, C., Mallevaey, T., Speak, A. O., Torres, D., Fontaine, J., Sheehan, K. C. F., Capron, M., Ryffel, B., Faveeuw, C., Leite de Moraes, M., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.08.017 · Cited by 276
Recent Advances in Immunomodulation and Vaccination Strategies Against Coccidiosis
Dalloul, R. A., & Lillehoj, H. S. (2005) · Avian Diseases · doi:10.1637/7306-11150r · Cited by 270
Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell–Mediated Tumor Immunity
Büll, C., Boltje, T. J., Balneger, N., Weischer, S. M., Wassink, M., van Gemst, J. J., Bloemendal, V. R., Boon, L., van der Vlag, J., Heise, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3376 · Cited by 268
Brownlie, R., Zhu, J., Allan, B., Mutwiri, G. K., Babiuk, L. A., Potter, A., & Griebel, P. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.06.002 · Cited by 263
An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy
Bonam, S. R., Partidos, C. D., Halmuthur, S. K. M., & Muller, S. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.002 · Cited by 261
Shirota, Y., Shirota, H., & Klinman, D. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101304 · Cited by 257
Self-citationZhu, G., Mei, L., Vishwasrao, H. D., Jacobson, O., Wang, Z., Liu, Y., Yung, B. C., Fu, X., Jin, A., Niu, G., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01386-7 · Cited by 255
mRNA as gene therapeutic: How to control protein expression
Tavernier, G., Andries, O., Demeester, J., Sanders, N. N., De Smedt, S. C., & Rejman, J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.020 · Cited by 232
Why Aging T Cells Fail: Implications for Vaccination
Haynes, L., & Swain, S. L. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.003 · Cited by 169
Targeting the TLR9–MyD88 pathway in the regulation of adaptive immune responses
Huang, X., & Yang, Y. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.501333 · Cited by 121
Jacobi, A. M., Goldenberg, D. M., Hiepe, F., Radbruch, A., Burmester, G. R., & Dörner, T. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.075762 · Cited by 127
Kortylewski, M., Kujawski, M., Herrmann, A., Yang, C., Wang, L., Liu, Y., Salcedo, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3031 · Cited by 122
“The simplicity of the natural ligands for TLR9, fragments of unmethylated double-stranded DNA, allows for a large-scale synthesis of TLR9 agonists optimized for stability and cell type–specific and species-specific activation (2).”
Kohchi, C., Inagawa, H., Nishizawa, T., Yamaguchi, T., Nagai, S., & Soma, G.-I. (2006) · Journal of Bioscience and Bioengineering · doi:10.1263/jbb.102.485 · Cited by 77
Kuchtey, J., Chefalo, P. J., Gray, R. C., Ramachandra, L., & Harding, C. V. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2244 · Cited by 66
Butterfield, J. S. S., Biswas, M., Shirley, J. L., Kumar, S. R. P., Sherman, A., Terhorst, C., Ling, C., & Herzog, R. W. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.013 · Cited by 35
Metadata
- Authors
- Klinman, D. M.
- Venue
- Nature Reviews Immunology
- Published
- 2004-04
- Volume
- 4
- Issue
- 4
- Pages
- 249-259
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W1999587028
- Cited by
- 1,012
- References
- 122
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.